IRC3 Antibody

What is IRF3 and what functional role does it play in immune signaling?

IRF3 is a key transcriptional regulator of type I interferon (IFN)-dependent immune responses with a critical role in innate immunity against DNA and RNA viruses . It functions as a central mediator that regulates transcription of type I IFN genes (IFN-alpha and IFN-beta) and IFN-stimulated genes by binding to interferon-stimulated response elements (ISREs) in their promoters . In uninfected cells, IRF3 exists in an inactive form in the cytoplasm. Following viral infection, double-stranded RNA exposure, or toll-like receptor signaling, IRF3 becomes phosphorylated, which triggers its activation . This activation leads to nuclear translocation, allowing IRF3 to initiate transcription of antiviral genes, orchestrating the body's defense mechanisms against pathogens . IRF3 acts as a more potent activator of the IFN-beta gene than IFN-alpha and plays crucial roles in both early and late phases of IFNA/B gene induction .

What types of IRF3 antibodies are available for research applications and how do they differ?

IRF3 antibodies are available in several formats with distinct characteristics:

Monoclonal antibodies like D-3 target specific epitopes near the C-terminus (amino acids 389-427), which is particularly important as this region contains regulatory phosphorylation sites critical for IRF3 activation . This specificity allows researchers to study activation dynamics and functional interactions within cells, providing valuable insights into immune signaling pathways .

What are the primary applications for IRF3 antibodies in immunological research?

IRF3 antibodies can be utilized across multiple experimental platforms:

• Western Blotting (WB): Enables detection of total and phosphorylated IRF3 forms at the expected molecular weight of approximately 47kDa .

• Immunohistochemistry with paraffin-embedded sections (IHC-P): Allows visualization of IRF3 distribution in tissue contexts .

• Flow Cytometry (FC): Permits quantitative assessment of IRF3 levels in cell populations .

• Immunofluorescence (IF): Enables subcellular localization studies, particularly nuclear translocation during activation .

• Immunoprecipitation (IP): Facilitates isolation of IRF3 protein complexes to study interaction partners .

• ELISA: Provides quantitative measurement of IRF3 levels in biological samples .

The recommended dilution ratios vary by application: WB typically requires 1:2000 dilution, while IHC-P, FC, and IF often use more concentrated antibody preparations (approximately 1:25) .

How should I select the appropriate IRF3 antibody for my specific experimental design?

When selecting an IRF3 antibody, consider these critical factors:

• Species Reactivity: Ensure the antibody recognizes IRF3 in your model organism. Available antibodies demonstrate reactivity with human and non-human primate (Green Monkey) IRF3 , while others can detect mouse and rat forms .

• Application Compatibility: Verify the antibody has been validated for your specific application. For example, the monoclonal antibody D-3 is validated for WB, IP, IF, IHC-P, and ELISA , while other antibodies may have different application profiles.

• Epitope Recognition: For phosphorylation studies, select antibodies that detect specific phosphorylation sites. For general IRF3 detection, antibodies targeting conserved regions are preferable. The C-terminal region (aa 389-427) contains regulatory phosphorylation sites critical for activation .

• Clonality Considerations: Monoclonal antibodies provide consistent epitope recognition across experiments but may be sensitive to epitope masking. Polyclonal antibodies recognize multiple epitopes, potentially increasing sensitivity but may show batch-to-batch variation.

• Format Requirements: Consider whether your experimental design requires conjugated antibodies (HRP, fluorophores) or specialized formats for particular applications .

Create a decision matrix weighing these factors against your experimental requirements to select the optimal antibody.

What validation approaches should I implement to confirm IRF3 antibody specificity?

A multi-faceted validation strategy should include:

• Positive and Negative Controls:

  • Positive: Cells known to express IRF3 (most nucleated cells)

  • Negative: IRF3 knockout cells or IRF3-depleted samples via siRNA

• Western Blot Validation:

  • Confirm single band at expected molecular weight (~47 kDa)

  • Verify band disappearance in knockout/knockdown samples

  • Test phospho-specific antibodies with appropriate stimulation (viral infection or TLR ligands)

• Immunofluorescence Cross-Validation:

  • Compare cytoplasmic localization in resting cells versus nuclear translocation in stimulated cells

  • Perform parallel staining with two different IRF3 antibodies recognizing distinct epitopes

• Blocking Peptide Competition:

  • Pre-incubate antibody with specific blocking peptide to confirm signal specificity

• Stimulus-Response Validation:

  • Verify increased IRF3 phosphorylation/nuclear translocation following appropriate stimuli

  • Confirm inhibition of these changes with pathway inhibitors

Document all validation steps systematically to ensure reproducibility and reliability of subsequent experimental findings.

What methodological considerations are essential for optimizing IRF3 antibody dilutions across different applications?

Optimization requires systematic titration for each application:

For Western Blotting:

• Begin with manufacturer's recommended dilution (typically 1:2000 for IRF3 antibodies)

• Perform a dilution series (e.g., 1:1000, 1:2000, 1:5000, 1:10000)

• Evaluate signal-to-noise ratio at each dilution

• Select the highest dilution that maintains clear specific signal while minimizing background

For Immunofluorescence/IHC:

• Start with recommended dilution (approximately 1:25 for many IRF3 antibodies)

• Create a matrix of antibody dilutions (1:10, 1:25, 1:50, 1:100) and antigen retrieval conditions

• Quantify signal intensity and background at each condition

• Select optimal conditions that maximize specific nuclear staining in stimulated samples

For Flow Cytometry:

• Begin with recommended dilutions (approximately 1:25)

• Test fixation and permeabilization conditions in parallel with antibody dilutions

• Use median fluorescence intensity and staining index to determine optimal conditions

Document optimization parameters including blocking reagents, incubation times/temperatures, and washing conditions to ensure reproducibility.

What is the optimal protocol for detecting IRF3 phosphorylation and activation via Western blotting?

A comprehensive Western blotting protocol for IRF3 phosphorylation detection includes:

Sample Preparation:

• Stimulate cells with appropriate inducers (viral infection, poly(I:C), or LPS)

• Prepare cytoplasmic and nuclear fractions separately to track translocation

• Add phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate) to lysis buffer

• Process samples rapidly at 4°C to prevent dephosphorylation

Gel Electrophoresis:

• Use 10% SDS-PAGE gels for optimal resolution of phosphorylated IRF3 species

• Load equivalent protein amounts (20-40 μg per lane)

• Include phosphatase-treated control samples to verify phospho-specific bands

Transfer and Detection:

• Use PVDF membrane (0.45 μm) for optimal protein retention

• Block with 5% BSA in TBST (phospho-specific antibodies) or 5% milk (total IRF3)

• Incubate with IRF3 antibody at 1:2000 dilution

• Visualize using appropriate detection system

To confirm activation status, parallel detection of phosphorylated and total IRF3 is recommended, along with markers of nuclear translocation. Phosphorylated IRF3 often appears as a slower-migrating band due to conformational changes, providing a useful visual confirmation of activation.

How can I effectively visualize IRF3 nuclear translocation using immunofluorescence techniques?

A systematic approach to visualize IRF3 nuclear translocation includes:

Cell Preparation:

• Culture cells on poly-L-lysine coated coverslips

• Create a time course of stimulation (0, 30, 60, 120, 240 minutes) with appropriate inducers

• Fix cells with 4% paraformaldehyde (10 minutes at room temperature)

• Permeabilize with 0.1% Triton X-100 (5 minutes)

Immunostaining:

• Block with 5% normal serum from the species of secondary antibody

• Incubate with IRF3 primary antibody (1:25 dilution) overnight at 4°C

• Apply fluorophore-conjugated secondary antibody (1:500) for 1 hour at room temperature

• Counterstain nuclei with DAPI (1:1000) for 5 minutes

• Mount with anti-fade mounting medium

Analysis:

• Capture images using confocal microscopy with consistent exposure settings

• Quantify nuclear/cytoplasmic signal ratio across multiple cells (>50 per condition)

• Present data as percentage of cells showing predominant nuclear IRF3 localization or as average nuclear/cytoplasmic fluorescence intensity ratio

This approach enables both qualitative visualization and quantitative assessment of IRF3 activation dynamics in response to various stimuli.

What approaches can I implement to study IRF3 in viral infection models?

Multiple complementary approaches enhance IRF3 functional studies in viral infection contexts:

In Vitro Models:

• Time-course experiments with live virus or viral mimetics (poly(I:C), 5'ppp-RNA)

• Parallel tracking of:

  • IRF3 phosphorylation (Western blot)

  • Nuclear translocation (immunofluorescence)

  • Target gene expression (RT-qPCR for IFN-β, IFIT1, CXCL10)

  • Virus replication (plaque assay, qPCR, reporter viruses)

• Comparison between wild-type cells and IRF3 knockout/knockdown cells to establish causality

Ex Vivo Approaches:

• Isolation of primary cells (macrophages, dendritic cells) from different genetic backgrounds

• Analysis of IRF3 activation following viral challenge

• Correlation with innate immune response markers

Advanced Techniques:

• Live cell imaging with fluorescently-tagged IRF3 to track real-time dynamics

• ChIP-seq to identify genome-wide IRF3 binding following infection

• Proximity labeling approaches to identify infection-specific IRF3 interaction partners

The combination of biochemical, imaging, and genomic approaches provides comprehensive insight into IRF3 function during viral infections. Comparison between different viral pathogens can reveal virus-specific modulation of IRF3 signaling pathways.

Why might I encounter inconsistent IRF3 detection in Western blot experiments and how can these issues be resolved?

Common challenges and their solutions include:

For accurate phospho-IRF3 detection, rapid sample processing is critical as phosphorylation signals can be lost quickly. Additionally, storing antibodies in small aliquots at -20°C prevents freeze-thaw degradation and maintains consistent detection sensitivity . Preparing standardized positive controls (e.g., poly(I:C)-stimulated cells) can provide a reference point across experiments.

How should I interpret discrepancies between IRF3 protein activity and gene expression data?

Discrepancies between IRF3 protein activation and downstream gene expression require systematic interpretation:

• Temporal Considerations:

  • IRF3 phosphorylation occurs rapidly (15-60 minutes post-stimulation)

  • Nuclear translocation follows (30-120 minutes)

  • Target gene transcription requires additional time (1-4 hours)

  • Protein production of target genes takes even longer (3-24 hours)

• Post-translational Regulation Analysis:

  • Examine IRF3 phosphorylation at multiple sites (Ser396, Ser386, Ser339)

  • Verify dimerization status via non-denaturing gels

  • Assess cofactor availability (CBP/p300) that influences transcriptional activity

• Epigenetic and Chromatin Context Evaluation:

  • Analyze chromatin accessibility at IRF3 target sites

  • Examine histone modifications at target promoters

  • Consider competing transcription factors or repressors

• Pathway Crosstalk Assessment:

  • Evaluate parallel activation of NF-κB and AP-1 pathways that cooperate with IRF3

  • Examine negative feedback regulators (SOCS proteins, A20)

  • Consider virus-specific antagonism of IRF3 signaling

When apparent discrepancies persist, consider cell type-specific factors, experimental timing, and the specific readouts being measured. A comprehensive time-course analysis of all pathway components often resolves apparent contradictions.

What essential controls should be included when studying IRF3 activation in response to immunological stimuli?

A rigorous experimental design includes multiple control types:

Positive Controls:

• Established IRF3 activators:

  • Poly(I:C) transfection (1 μg/mL, 2-4 hours) for RIG-I pathway

  • LPS treatment (100 ng/mL, 1-2 hours) for TLR4 pathway

  • 2'3'-cGAMP (2-5 μg/mL) for STING pathway

• IFN-β promoter reporter assays for functional validation

Negative Controls:

• Genetic controls:

  • IRF3 knockout/knockdown cells

  • Pathway-specific controls (MAVS-/-, STING-/-, TBK1-/-)

• Pharmacological inhibitors:

  • TBK1/IKKε inhibitors (BX-795, MRT67307)

  • Pathway-specific inhibitors

Specificity Controls:

• IRF3-S396A phosphorylation site mutants

• IRF7 activation monitoring (parallel IRF family member)

• Nuclear/cytoplasmic fractionation quality controls

How can ChIP-seq approaches be effectively combined with IRF3 antibodies to characterize genome-wide binding patterns?

Integrating ChIP-seq with IRF3 antibodies requires specialized methodological considerations:

Experimental Design:

• Stimulation Timing: Perform careful time-course experiments (1, 2, 4, 6 hours post-stimulation) to capture dynamic binding events

• Crosslinking Optimization: Test both formaldehyde (1%, 10 minutes) and dual crosslinking (DSG followed by formaldehyde) to capture indirect DNA associations

• Chromatin Fragmentation: Optimize sonication conditions to achieve 200-400bp fragments for high-resolution binding profiles

IRF3 Antibody Considerations:

• Validation for ChIP: Perform preliminary ChIP-qPCR at established IRF3 binding sites (IFN-β promoter) to verify enrichment

• Antibody Selection: Use antibodies recognizing regions outside the DNA-binding domain to avoid epitope masking

• Input Control: Process a minimum of 2% input chromatin in parallel for normalization

Bioinformatic Analysis Pipeline:

• Peak Calling: Use MACS2 with parameters optimized for transcription factors (narrow peaks)

• Motif Analysis: Perform de novo motif discovery and compare with established IRF3 binding motifs (ISRE elements)

• Integration with Multi-omic Data:

  • RNA-seq to correlate binding with expression changes

  • ATAC-seq to assess chromatin accessibility

  • H3K27ac ChIP-seq to identify active enhancers co-bound by IRF3

This approach reveals stimulus-specific and cell type-specific IRF3 binding patterns, providing insight into the regulatory networks governing innate immune responses.

What methodological approaches enable effective characterization of IRF3 protein interactions and regulatory complexes?

Multiple complementary techniques enhance IRF3 interaction studies:

Immunoprecipitation-Based Methods:

• Co-immunoprecipitation with IRF3 antibodies:

  • Use mild lysis conditions (1% NP-40) to preserve interactions

  • Include phosphatase inhibitors to maintain activation-dependent interactions

  • Validate with reciprocal IPs using antibodies against suspected partners

• Tandem Affinity Purification:

  • Generate cells expressing tagged IRF3 (e.g., FLAG-HA-IRF3)

  • Perform sequential purification to reduce background

  • Identify interaction partners via mass spectrometry

Proximity-Based Methods:

• BioID or TurboID:

  • Express IRF3 fused to promiscuous biotin ligase

  • Identify proximal proteins via streptavidin pulldown

  • Compare interactomes between resting and stimulated conditions

• APEX2 Proximity Labeling:

  • Express IRF3-APEX2 fusion

  • Perform rapid (1 minute) biotinylation upon H₂O₂ addition

  • Enables temporal resolution of dynamic complexes

Imaging-Based Approaches:

• Proximity Ligation Assay (PLA):

  • Visualize endogenous IRF3 interactions in situ

  • Quantify interaction signals in different subcellular compartments

  • Track interaction dynamics following stimulation

• Förster Resonance Energy Transfer (FRET):

  • Express IRF3 fused to donor fluorophore

  • Express interaction partners fused to acceptor fluorophore

  • Measure real-time interaction dynamics in living cells

Integrating these approaches provides a comprehensive view of the IRF3 interactome under different activation states and cellular contexts.

How can I design experiments to investigate cross-talk between IRF3 and parallel signaling pathways in innate immunity?

Systematic investigation of signaling cross-talk requires multi-dimensional experimental design:

Genetic Manipulation Approaches:

• Combinatorial knockout/knockdown:

  • Generate single and double knockouts of IRF3 and parallel pathway components (e.g., IRF3/NF-κB)

  • Assess synergistic or antagonistic effects on immune responses

  • Perform rescue experiments with wild-type and mutant constructs

• Domain swap/point mutation analysis:

  • Modify specific interaction surfaces or phosphorylation sites

  • Assess impact on pathway integration

  • Create separation-of-function mutants affecting specific cross-talk mechanisms

Temporal Resolution Studies:

• High-resolution time course:

  • Track pathway activation markers at 5-15 minute intervals

  • Correlate activation dynamics between IRF3 and other pathways

  • Use mathematical modeling to infer causal relationships

• Selective pathway inhibition:

  • Apply inhibitors at different time points relative to stimulation

  • Determine temporal windows of pathway interdependence

  • Identify rate-limiting steps in integrated responses

Spatial Organization Analysis:

• Advanced microscopy:

  • Super-resolution imaging of signaling complexes

  • Track co-localization of pathway components in real-time

  • Visualize signaling platforms (e.g., MAVS aggregates, STING translocation)

• Organelle-specific signaling:

  • Isolate pathway components from different subcellular compartments

  • Analyze compartment-specific protein modifications

  • Identify organelle-specific interaction partners

Integration of these approaches with systems-level analysis (phosphoproteomics, transcriptomics) provides comprehensive insight into the multifaceted cross-talk between IRF3 and parallel innate immune signaling pathways.